These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31163444)

  • 21. [Detoxification of patients with GHB dependence].
    de Weert-van Oene GH; Schellekens AF; Dijkstra BA; Kamal R; de Jong CA
    Tijdschr Psychiatr; 2013; 55(11):885-90. PubMed ID: 24242149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gamma-butyrolactone and 1,4-butanediol: abused analogues of gamma-hydroxybutyrate.
    Palmer RB
    Toxicol Rev; 2004; 23(1):21-31. PubMed ID: 15298490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gamma-hydroxybutyrate withdrawal syndrome.
    Dyer JE; Roth B; Hyma BA
    Ann Emerg Med; 2001 Feb; 37(2):147-53. PubMed ID: 11174231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The gamma-hydroxybutyrate withdrawal syndrome.
    Tarabar AF; Nelson LS
    Toxicol Rev; 2004; 23(1):45-9. PubMed ID: 15298492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baclofen to Prevent Relapse in Gamma-Hydroxybutyrate (GHB)-Dependent Patients: A Multicentre, Open-Label, Non-Randomized, Controlled Trial.
    Beurmanjer H; Kamal RM; de Jong CAJ; Dijkstra BAG; Schellekens AFA
    CNS Drugs; 2018 May; 32(5):437-442. PubMed ID: 29651711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose benzodiazepine dependence: a qualitative study of patients' perception on cessation and withdrawal.
    Liebrenz M; Gehring MT; Buadze A; Caflisch C
    BMC Psychiatry; 2015 May; 15():116. PubMed ID: 25968120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gamma-hydroxybutyrate detoxification by titration and tapering.
    de Jong CA; Kamal R; Dijkstra BA; de Haan HA
    Eur Addict Res; 2012; 18(1):40-5. PubMed ID: 22142784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intoxication by gamma hydroxybutyrate and related analogues: Clinical characteristics and comparison between pure intoxication and that combined with other substances of abuse.
    Miró Ò; Galicia M; Dargan P; Dines AM; Giraudon I; Heyerdahl F; Hovda KE; Yates C; Wood DM; Liakoni E; Liechti M; Jürgens G; Pedersen CB; O'Connor N; Markey G; Moughty A; Lee C; O'Donohoe P; Sein Anand J; Puiguriguer J; Homar C; Eyer F; Vallersnes OM; Persett PS; Chevillard L; Mégarbane B; Paasma R; Waring WS; Põld K; Rabe C; Kabata PM
    Toxicol Lett; 2017 Aug; 277():84-91. PubMed ID: 28579487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical management of gamma-hydroxybutyrate (GHB) withdrawal delirium with CIWA-Ar protocol.
    Liao PC; Chang HM; Chen LY
    J Formos Med Assoc; 2018 Dec; 117(12):1124-1127. PubMed ID: 29933901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Within-patient variability in clinical presentation of gamma-hydroxybutyrate withdrawal: a case report.
    Glasper A; McDonough M; Bearn J
    Eur Addict Res; 2005; 11(3):152-4. PubMed ID: 15990433
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies.
    McDaniel CH; Miotto KA
    J Psychoactive Drugs; 2001; 33(2):143-9. PubMed ID: 11476261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Neurobiological Mechanisms of Gamma-Hydroxybutyrate Dependence and Withdrawal and Their Clinical Relevance: A Review.
    Kamal RM; van Noorden MS; Franzek E; Dijkstra BA; Loonen AJ; De Jong CA
    Neuropsychobiology; 2016; 73(2):65-80. PubMed ID: 27003176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses.
    Leone MA; Vigna-Taglianti F; Avanzi G; Brambilla R; Faggiano F
    Cochrane Database Syst Rev; 2010 Feb; (2):CD006266. PubMed ID: 20166080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal.
    Miotto K; Darakjian J; Basch J; Murray S; Zogg J; Rawson R
    Am J Addict; 2001; 10(3):232-41. PubMed ID: 11579621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The behavioural profile of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol in humans.
    Bosch OG; Seifritz E
    Brain Res Bull; 2016 Sep; 126(Pt 1):47-60. PubMed ID: 26855327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Effect of Co-occurring Substance Use on Gamma-hydroxybutyric Acid Withdrawal Syndrome.
    Kamal RM; Dijkstra BA; Loonen AJ; De Jong CA
    J Addict Med; 2016; 10(4):229-35. PubMed ID: 27310146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensive sex partying with gamma-hydroxybutyrate: factors associated with using gamma-hydroxybutyrate for chemsex among Australian gay and bisexual men - results from the Flux Study.
    Hammoud MA; Bourne A; Maher L; Jin F; Haire B; Lea T; Degenhardt L; Grierson J; Prestage G
    Sex Health; 2018 Apr; 15(2):123-134. PubMed ID: 29268075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known.
    van Noorden MS; van Dongen LC; Zitman FG; Vergouwen TA
    Gen Hosp Psychiatry; 2009; 31(4):394-6. PubMed ID: 19555805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What constitutes problematic khat use? An exploratory mixed methods study in Ethiopia.
    Mihretu A; Teferra S; Fekadu A
    Subst Abuse Treat Prev Policy; 2017 Mar; 12(1):17. PubMed ID: 28327160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GHB, GBL and 1,4-BD addiction.
    Brunt TM; van Amsterdam JG; van den Brink W
    Curr Pharm Des; 2014; 20(25):4076-85. PubMed ID: 24001290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.